|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1997-10-20
|
|
pubmed:abstractText |
A phase I study was designed for the amalgamation of two previously studied antisarcoma regimens (ifosfamide+doxorubicin and mitomycin+doxorubicin+cisplatin) supported by molgramostim. Thus, we hoped to develop a better regimen for the treatment of advanced sarcomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
637-41
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9296215-Adult,
pubmed-meshheading:9296215-Antineoplastic Agents,
pubmed-meshheading:9296215-Cisplatin,
pubmed-meshheading:9296215-Doxorubicin,
pubmed-meshheading:9296215-Drug Synergism,
pubmed-meshheading:9296215-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:9296215-Humans,
pubmed-meshheading:9296215-Ifosfamide,
pubmed-meshheading:9296215-Mesna,
pubmed-meshheading:9296215-Mitomycins,
pubmed-meshheading:9296215-Recombinant Proteins,
pubmed-meshheading:9296215-Sarcoma,
pubmed-meshheading:9296215-Survival Analysis
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?
|
|
pubmed:affiliation |
Division of Medical oncology, Mayo Clinic, Rochester, MN, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Clinical Trial, Phase I
|
